IL2 and graft versus host disease: Moreover, there are ongoing clinical trials evaluating the safety and efficacy of Efavaleukin Alfa, a human IL-2 mutein Fc fusion protein selectively expanding human Tregs in vivo, being evaluated in GvHD (NCT03422627) and systemic lupus erythematosus (NCT03451422).